{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/634549cdd950350012c90fc5/6afc881b5a2e6307a89e4227?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"How can established oncology CAR T-cell therapy pathways be adapted for rheumatology? ","description":"<p>The Lupus Hub was pleased to speak with Ruth Pepper, Royal Free Hospital and University College London Hospitals NHS Foundation Trust (UCLH), London, UK. We asked, How can established oncology CAR T-cell therapy pathways be adapted for rheumatology? </p><p><br></p><p>During this interview, Pepper discusses how established approaches from hematology and oncology can be applied to the treatment of autoimmune diseases, including systemic lupus erythematosus (SLE). She describes how existing hematology infrastructure, expertise, and protocols for chimeric antigen receptor (CAR) T-cell therapy support the delivery of clinical trials in patients with treatment-refractory lupus. Pepper also highlights the importance of multidisciplinary collaboration between hematology, rheumatology, and nephrology teams in treatment delivery, monitoring for potential complications, and coordinating patient care. </p><p><br></p><p>Intended for healthcare professionals. This educational resource is independently supported by Autolus. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. </p>","author_name":"Scientific Education Support"}